Sandoz Seeks U.S. High Court Review On Law Over Biologics, Patents
WASHINGTON, D.C. — An appellate court erred in finding that biosimilar makers must wait until their products receive U.S. Food and Drug Administration approval before providing 180-day advance notice of sales,...To view the full article, register now.
Already a subscriber? Click here to view full article